Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: The optimal care study

Blood

Volumn 115, Issue 10, 2010, Pages 1886-1892

  Taher, Ali T ^a   Musallam, Khaled M ^a   Karimi, Mehran ^b   El Beshlawy, Amal ^c   Belhoul, Khawla ^d   Daar, Shahina ^e   Saned, Mohamed Salaheldin ^d   El Chafic, Abdul Hamid ^a   Fasulo, Maria R ^f   Cappellini, Maria D ^f  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c CAIRO UNIVERSITY   (Egypt)

^d Al Wasl Hospital   (United Arab Emirates)

^e SULTAN QABOOS UNIVERSITY   (Oman)

^f UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYUREA;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD TRANSFUSION; CHILD; CHOLELITHIASIS; CLINICAL EVALUATION; DIABETES MELLITUS; ENDEMIC DISEASE; ENDOCRINE DISEASE; EXTRAMEDULLARY HEMATOPOIESIS; FEMALE; HEART FAILURE; HUMAN; HYPOGONADISM; HYPOTHYROIDISM; IRON CHELATION; LEG ULCER; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; MULTIVARIATE ANALYSIS; OSTEOPOROSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; RETROSPECTIVE STUDY; SCHOOL CHILD; SPLENECTOMY; THALASSEMIA; THROMBOSIS;

EID: 77950420281     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-09-243154     Document Type: Article

References (43)

1. Galanello R, Cao A. Relationship between genotype and phenotype: thalassemia intermedia. Ann NY Acad Sci. 1998;850:325-333. (Pubitemid 128714088)
2. Weatherall D. The molecular basis for phenotypic variability of the common thalassaemias. Mol Med Today. 1995;1(1):15-20.
3. Taher A, Ismaeel H, Cappellini MD. Thalassaemia intermedia: revisited. Blood Cells Mol Dis. 2006;37(1):12-20.
4. Olivieri NF. The beta-thalassemias. N Engl J Med. 1999;341(2):99-109.
5. Cappellini MD, Cohen A, Eleftheriou A, Piga A, Porter J, Taher A. Guidelines for the Clinical Management of Thalassaemia. 2nd rev. ed. NicosiaCyprus: Thalassaemia International Federation; 2008.
6. Taher A, Abou-Mourad Y, Abchee A, Zallouaa P, Shamseddine A. Pulmonary thromboembolism in beta-thalassemia intermedia: are we aware of this complication? Hemoglobin. 2002;26(2):107-112.
7. Aessopos A, Farmakis D, Karagiorga M, et al. Cardiac involvement in thalassemia intermedia: a multicenter study. Blood. 2001;97(11):3411-3416.
8. Taher AT, Otrock ZK, Uthman I, Cappellini MD. Thalassemia and hypercoagulability. Blood Rev. 2008;22(5):283-292.
9. Origa R, Galanello R, Ganz T, et al. Liver iron concentrations and urinary hepcidin in beta-thalassemia. Haematologica. 2007;92(5):583-588. (Pubitemid 350144260)
10. Aessopos A, Farmakis D, Deftereos S, et al. Thalassemia heart disease: a comparative evaluation of thalassemia major and thalassemia intermedia. Chest. 2005;127(5):1523-1530. (Pubitemid 46218775)
11. Isma'eel H, El Chafic AH, El Rassi F, et al. Relation between iron-overload indices, cardiac echo-Doppler and biochemical markers in thalassemia intermedia. Am J Cardiol. 2008;102(3):363-367.
12. Karimi M, Darzi H, Yavarian M. Haematologic and clinical responses of thalassemia intermedia patients to hydroxyurea during 6 years of therapy in Iran. J Pediatr Hematol Oncol. 2005;27(7):380-385. (Pubitemid 41077027)
13. Cossu P, Toccafondi C, Vardeu F, et al. Iron overload and desferrioxamine chelation therapy in beta-thalassemia intermedia. Eur J Pediatr. 1981;13(3):267-271.
14. Pippard MJ, Weatherall DJ. Iron balance and the management of iron overload in beta-thalassemia intermedia. Birth Defects Orig Artic Ser. 1988;23(5B):29-33.
15. Pootrakul P, Sirankapracha P, Sankote J, et al. Clinical trial of deferiprone iron chelation therapy in beta-thalassaemia/haemoglobin E patients in Thailand. Br J Haematol. 2003;122(2):305-310. (Pubitemid 36859618)
16. Camaschella C, Cappellini MD. Thalassemia intermedia. Haematologica. 1995;80(1):58-68.
17. Cappellini MD, Musallam KM, Cesaretti C, Taher A. Thalassemia intermedia. In: Beaumont C, Beris P, Beuzard Y, Brugnara C, eds. Disorders of Erythropoiesis, Erythrocytes and Iron Metabolism. Genoa, Italy: Forum Service Editore; 2009:286-309.
18. Barst RJ, McGoon M, Torbicki A, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43(supp 12):S40-S47.
19. Kleber FX, Niemoller L, Doering W. Impact of converting enzyme inhibition on progression of chronic heart failure: results of the Munich mild heart failure trial. Br Heart J. 1992;67(4):289-296.
20. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193-203.
21. Baskin HJ, Cobin RH, Duick DS, et al; American Association of Clinical Endocrinologists: American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism. Endocr Pract. 2002;8(6):457-469.
22. El-Hajj Fuleihan G, Baddoura R, Awada H, Arabi A, Okais J. First update of the Lebanese guidelines for osteoporosis assessment and treatment. J Clin Densitom. 2008;11(3):383-396.
23. Fung EB, Harmatz PR, Lee PD, et al. Multi-Centre Study of Iron Overload Research Group: increased prevalence of iron-overload associated endocrinopathy in thalassaemia versus sickle-cell disease. Br J Haematol. 2006;135(4):574-582.
24. Taher A, Isma'eel H, Mehio G, et al. Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran. Thromb Haemost. 2006;96(4):488-491. (Pubitemid 44560684)
25. Cappellini MD, Robbiolo L, Bottasso BM, Coppola R, Fiorelli AP, Mannucci AP. Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermedia. Br J Haematol. 2000;111(2):467-473. (Pubitemid 32009338)
26. Cappellini MD, Grespi E, Cassinerio E, Bignamini D, Fiorelli G. Coagulation and splenectomy: an overview. Ann N Y Acad Sci. 2005; 1054:317-324.
27. Atichartakarn V, Angchaisuksiri P, Aryurachai K, Chuncharunee S, Thakkinstian A. In vivo platelet activation and hyperaggregation in hemoglobin E/beta-thalassemia: a consequence of splenectomy. Int J Hematol. 2003;77(3):299-303. (Pubitemid 37121859)
28. Atichartakarn V, Angchaisuksiri P, Aryurachai K, et al. Relationship between hypercoagulable state and erythrocyte phosphatidylserine exposure in splenectomized haemoglobin E/beta thalassaemic patients. Br J Haematol. 2002;118(3):893-898.
29. Atichartakarn V, Likittanasombat K, Chuncharunee S, et al. Pulmonary arterial hypertension in previously splenectomized patients with beta-thalassemic disorders. Int J Hematol. 2003;78(2):139-145. (Pubitemid 37021954)
30. Tavazzi D, Duca L, Graziadei G, Comino A, Fiorelli G, Cappellini MD. Membrane-bound iron contributes to oxidative damage of β-thalassaemia intermedia erythrocytes. Br J Haematol. 2001;112(1):48-50. (Pubitemid 32151148)
31. Cadili A, de Gara C. Complications of splenectomy. Am J Med. 2008;121(5):371-375.
32. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89(10):1187-1193. (Pubitemid 39390442)
33. Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med. 1994;331(9):574-578. (Pubitemid 24265699)
34. Aessopos A, Kati M, Farmakis D. Heart disease in thalassemia intermedia: a review of the underlying pathophysiology. Haematologica. 2007;92(5):658-665. (Pubitemid 350144268)
35. Aessopos A, Kati M, Meletis J. Thalassemia intermedia today: should patients regularly receive transfusions? Transfusion. 2007;47(5):792-800. (Pubitemid 46668992)
36. Eder AF, Chambers LA. Noninfectious complications of blood transfusion. Arch Pathol Lab Med. 2007;131(5):708-718.
37. Olivieri NF. Reactivation of fetal hemoglobin in patients with beta-thalassemia. Semin Hematol. 1996;33(1):24-42. (Pubitemid 26064766)
38. Arruda VR, Lima CS, Saad ST, Costa FF. Successful use of hydroxyurea in beta-thalassemia major. N Engl J Med. 1997;336(13):964.
39. Bradai M, Abad MT, Pissard S, Lamraoui F, Skopinski L, de Montalembert M. Hydroxyurea can eliminate transfusion requirements in children with severe beta-thalassemia. Blood. 2003;102(4):1529-1530. (Pubitemid 36988066)
40. Dixit A, Chatterjee TC, Mishra P, et al. Hydroxyurea in thalassemia intermedia: a promising therapy. Ann Hematol. 2005;84(7):441-446. (Pubitemid 40867920)
41. Taher A, El Rassi F, Isma'eel H, Koussa S, Inati A, Cappellini MD. Correlation of liver iron concentration determined by R2 MRI with serum ferritin in patients with thalassemia intermedia. Haematologica. 2008;93(10):1584-1586.
42. Musallam K, Cappellini MD, Taher A. Challenges associated with prolonged survival of patients with thalassemia: transitioning from childhood to adulthood. Pediatrics. 2008;121(5):e1426-e1429.
43. Derchi G, Forni GL, Formisano F, et al. Efficacy and safety of sildenafil in the treatment of severe pulmonary hypertension in patients with hemoglobinopathies. Haematologica. 2005;90(4):452-458. (Pubitemid 40592887)